• Wei-Ying Jen, Joanne Yoong, Xin Liu, Melinda Si Yun Tan, Wee Joo Chng, and Yen-Lin Chee.
• Department of Haematology-Oncology, National University Cancer Institute, Singapore.
• Patient Prefer Adher. 2020 Jan 1; 14: 301-308.

IntroductionThe number of treatment options for myeloma and indolent lymphoma are expanding at an exponential rate, with few direct head-to-head comparisons on which to base efficacy measures. We sought to understand how patients, their caregivers and physicians weigh treatment characteristics in order to come to a decision on which treatment option to pursue.MethodsPatients, their caregivers and physicians were recruited and interviewed until data saturation was reached. A qualitative, thematic analysis was done to identify themes important to each stakeholder.ResultsWe found that, while all three groups valued efficacy the most, the consideration of other secondary characteristics of the treatment, such as cost, toxicity and logistical issues all differed subtly between the different groups. Patients valued minimising cost and toxicity, even at small trade-offs in efficacy. Caregivers and physicians valued efficacy foremost.ConclusionAcknowledging and managing these differences is paramount because they influence shared decision-making and may affect patient outcomes in the short term, as well as their more general well-being in the long term.© 2020 Jen et al.

4 keywords...

hide…